Drug Trial Radar · NCT02369146
To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults
Last checked: Nov 19, 2026Latest source record: Oct 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Jun 2015
Primary completion
Jul 2016
Study completion Jul 2016
Sponsor
- Lead sponsor
- United BioPharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Taipei Veterans General Hospital, Taiwan; Kaohsiung Veterans General Hospital.; Kaohsiung Medical University Chung-Ho Memorial Hospital
- First posted
- Feb 23, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase II study is to evaluate the safety, tolerability and efficacy of two multi-dose regimens of UB-421 monotherapy in replacement of HAART in HIV-1 infected adults with virological suppression.
Conditions
- HIV-1 Infection
Interventions
UB-421Drug
The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial). Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse eventsTime frame: 17 weeks for cohort 1, 25 weeks for cohort 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taipei Veterans General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.